Nov 11, 2020 / 07:45PM GMT
Martin Douglas Auster - Crédit Suisse AG - Research Division - Research Analyst
Okay. Hello, everybody. Welcome. Thanks for joining us. This is -- I'm Marty Auster. I'm the lead smid cap biotech analyst at Crédit Suisse. You are tuning in again to the 29th Annual Virtual Healthcare Conference. Right now, we're being joined by Intellia Therapeutics. I've got John Leonard, CEO with me. John, really happy to have you here. We've got a number of questions. We're hoping to kind of throw at you.
Questions and Answers:
Martin Douglas Auster - Crédit Suisse AG - Research Division - Research AnalystMaybe if you could start with just maybe a quick introduction of Intellia and kind of a little bit about just the vision going forward.
John M. Leonard - Intellia Therapeutics, Inc. - President, CEO & Director
So thanks, Marty. Happy to be here. So Intellia is a CRISPR/Cas9-based gene editing company, and a leader in the space, and we've been active now for a few